Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,602.40
(
1.04%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
95.83
(
-0.70%
)
Bitcoin
71,323.00
(
1.14%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biocqr

Send PM Follow Ignore
Followers 50
Posts 3530
Boards Moderated 0
Alias Born 08/24/2005

biocqr

Member Level

Re: DewDiligence post# 189976

Thursday, 04/16/2015 11:05:14 AM

Thursday, April 16, 2015 11:05:14 AM

Post# of 257275
Thank you! It appears that AAVL is exploring two paths for AVA-101 approval... as a direct competitor to Lucentis/Avastin/Eylea and as rescue therapy for anti-VEGF refractory patients. Given the decline in efficacy over time with anti-VEGF injections, the refractory population could be substantial. Do you believe AVA-101 might have a better chance as rescue therapy?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today